Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients
Cardiovascular (CV) events are the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), including those patients on peritoneal dialysis (PD). Fibroblast growth factor 23 (FGF23) has been associated with left ventricular hypertrophy (LVH) and mortality in patients w...
Gespeichert in:
| Veröffentlicht in: | Clinical nephrology 2016-03, Vol.85 (3), p.135-141 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 3 |
| container_start_page | 135 |
| container_title | Clinical nephrology |
| container_volume | 85 |
| creator | Sarmento-Dias, Margarida Santos-Araújo, Carla Poínhos, Rui Oliveira, Bruno Silva, Isabell Soares Silva, Liliana Simões Sousa, Maria João Correia, Flora Pestana, Manuel |
| description | Cardiovascular (CV) events are the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), including those patients on peritoneal dialysis (PD). Fibroblast growth factor 23 (FGF23) has been associated with left ventricular hypertrophy (LVH) and mortality in patients with CKD. However, the role of FGF23 in uremic vasculopathy remains unclear. In this study, we aimed to assess the relationship between FGF23 and LVH, endothelial dysfunction, vascular calcification, and arterial stiffness in 48 stable PD patients.
Left ventricular mass index (LVMI) was assessed using 2-D echocardiography. Intact FGF23 blood levels were evaluated using an ELISA kit (Immutopics, Inc., San Clemente, CA, USA). Reactive hyperemia index (RHI) is a surrogate marker of endothelial dysfunction and the augmentation index (AI) is a surrogate marker of arterial stiffness. Both were assessed using peripheral arterial tonometry (EndoPAT 2000). Vascular calcification (VC) was assessed using the Adragão score.
In unadjusted analysis; FGF23 was positively correlated with serum Pi (r = 0.487, p < 0.001), serum urea (r = 0.351, p = 0.015), serum creatinine (r = 0.535, p < 0.001), dialysis vintage (r = 0.309, p = 0.033), and LVMI (r = 0.369, p = 0.027) and was negatively correlated with age (r = -0.343, p = 0.017), residual renal function (r = -0.359, p < 0.012), and AI (r = -0.304, p = 0.038). In multivariate adjusted analysis, FGF23 was associated with LVMI (β = 0.298, p = 0.041), serum Pi (β = 0.345, p = 0.018), and age (β = -0.372, p = 0.007) independent of dialysis vintage, gender, residual renal function (RRF), albumin, C-reactive protein and systolic blood pressure. There were no associations found between FGF23 and RHI, AI, or VC in multivariable- adjusted models.
Our results show that FGF23 is associated with LVH but not with endothelial dysfunction, arterial stiffness, or vascular calcification in PD patients. |
| doi_str_mv | 10.5414/CN108716 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762959306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1762959306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-477a8e1cc6a86ab8ba2ef288b0d6c131e0457d5ade94c9eb448322adc7c4ad613</originalsourceid><addsrcrecordid>eNpFkLFOwzAURT2AaClIfAHyyEDAjp3EGVFFAQnBAnP04rwQozQOttMqn8BfE9QWpjfco_OkQ8gFZzeJ5PJ2-cKZynh6ROZMMB4xKdiMnHr_yVjMlFAnZBanSgjB2Jx8r0zpbNmCD_TD2W1oaA06WEdjQY2n4L3VBgJWdGumscU60A12wRk9tOBoM_bogrN9M17TzoYdNjhcG0034CfK9hCakZqOTqgJtkNoaWWgHf30YRrN5PNn5LiG1uP5_i7I--r-bfkYPb8-PC3vniMtOAuRzDJQyLVOQaVQqhJirGOlSlalmguOTCZZlUCFudQ5llIqEcdQ6UxLqFIuFuRq5-2d_RrQh2JtvMa2hQ7t4AuepXGe5IKl_6h21nuHddE7swY3FpwVv7GLQ-wJvdxbh3KN1R94KC1-AGggfzA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762959306</pqid></control><display><type>article</type><title>Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Sarmento-Dias, Margarida ; Santos-Araújo, Carla ; Poínhos, Rui ; Oliveira, Bruno ; Silva, Isabell Soares ; Silva, Liliana Simões ; Sousa, Maria João ; Correia, Flora ; Pestana, Manuel</creator><creatorcontrib>Sarmento-Dias, Margarida ; Santos-Araújo, Carla ; Poínhos, Rui ; Oliveira, Bruno ; Silva, Isabell Soares ; Silva, Liliana Simões ; Sousa, Maria João ; Correia, Flora ; Pestana, Manuel</creatorcontrib><description>Cardiovascular (CV) events are the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), including those patients on peritoneal dialysis (PD). Fibroblast growth factor 23 (FGF23) has been associated with left ventricular hypertrophy (LVH) and mortality in patients with CKD. However, the role of FGF23 in uremic vasculopathy remains unclear. In this study, we aimed to assess the relationship between FGF23 and LVH, endothelial dysfunction, vascular calcification, and arterial stiffness in 48 stable PD patients.
Left ventricular mass index (LVMI) was assessed using 2-D echocardiography. Intact FGF23 blood levels were evaluated using an ELISA kit (Immutopics, Inc., San Clemente, CA, USA). Reactive hyperemia index (RHI) is a surrogate marker of endothelial dysfunction and the augmentation index (AI) is a surrogate marker of arterial stiffness. Both were assessed using peripheral arterial tonometry (EndoPAT 2000). Vascular calcification (VC) was assessed using the Adragão score.
In unadjusted analysis; FGF23 was positively correlated with serum Pi (r = 0.487, p < 0.001), serum urea (r = 0.351, p = 0.015), serum creatinine (r = 0.535, p < 0.001), dialysis vintage (r = 0.309, p = 0.033), and LVMI (r = 0.369, p = 0.027) and was negatively correlated with age (r = -0.343, p = 0.017), residual renal function (r = -0.359, p < 0.012), and AI (r = -0.304, p = 0.038). In multivariate adjusted analysis, FGF23 was associated with LVMI (β = 0.298, p = 0.041), serum Pi (β = 0.345, p = 0.018), and age (β = -0.372, p = 0.007) independent of dialysis vintage, gender, residual renal function (RRF), albumin, C-reactive protein and systolic blood pressure. There were no associations found between FGF23 and RHI, AI, or VC in multivariable- adjusted models.
Our results show that FGF23 is associated with LVH but not with endothelial dysfunction, arterial stiffness, or vascular calcification in PD patients.</description><identifier>ISSN: 0301-0430</identifier><identifier>DOI: 10.5414/CN108716</identifier><identifier>PMID: 26833300</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Age Factors ; Biomarkers - blood ; Blood Pressure - physiology ; C-Reactive Protein - analysis ; Creatinine - blood ; Cross-Sectional Studies ; Echocardiography - methods ; Endothelium, Vascular - pathology ; Female ; Fibroblast Growth Factors - blood ; Humans ; Hyperemia - blood ; Hypertrophy, Left Ventricular - blood ; Hypertrophy, Left Ventricular - etiology ; Kidney - physiopathology ; Male ; Middle Aged ; Peritoneal Dialysis - adverse effects ; Phosphates - blood ; Renal Insufficiency, Chronic - blood ; Renal Insufficiency, Chronic - complications ; Serum Albumin - analysis ; Urea - blood ; Uremia - complications ; Vascular Calcification - etiology ; Vascular Stiffness - physiology</subject><ispartof>Clinical nephrology, 2016-03, Vol.85 (3), p.135-141</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-477a8e1cc6a86ab8ba2ef288b0d6c131e0457d5ade94c9eb448322adc7c4ad613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26833300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarmento-Dias, Margarida</creatorcontrib><creatorcontrib>Santos-Araújo, Carla</creatorcontrib><creatorcontrib>Poínhos, Rui</creatorcontrib><creatorcontrib>Oliveira, Bruno</creatorcontrib><creatorcontrib>Silva, Isabell Soares</creatorcontrib><creatorcontrib>Silva, Liliana Simões</creatorcontrib><creatorcontrib>Sousa, Maria João</creatorcontrib><creatorcontrib>Correia, Flora</creatorcontrib><creatorcontrib>Pestana, Manuel</creatorcontrib><title>Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients</title><title>Clinical nephrology</title><addtitle>Clin Nephrol</addtitle><description>Cardiovascular (CV) events are the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), including those patients on peritoneal dialysis (PD). Fibroblast growth factor 23 (FGF23) has been associated with left ventricular hypertrophy (LVH) and mortality in patients with CKD. However, the role of FGF23 in uremic vasculopathy remains unclear. In this study, we aimed to assess the relationship between FGF23 and LVH, endothelial dysfunction, vascular calcification, and arterial stiffness in 48 stable PD patients.
Left ventricular mass index (LVMI) was assessed using 2-D echocardiography. Intact FGF23 blood levels were evaluated using an ELISA kit (Immutopics, Inc., San Clemente, CA, USA). Reactive hyperemia index (RHI) is a surrogate marker of endothelial dysfunction and the augmentation index (AI) is a surrogate marker of arterial stiffness. Both were assessed using peripheral arterial tonometry (EndoPAT 2000). Vascular calcification (VC) was assessed using the Adragão score.
In unadjusted analysis; FGF23 was positively correlated with serum Pi (r = 0.487, p < 0.001), serum urea (r = 0.351, p = 0.015), serum creatinine (r = 0.535, p < 0.001), dialysis vintage (r = 0.309, p = 0.033), and LVMI (r = 0.369, p = 0.027) and was negatively correlated with age (r = -0.343, p = 0.017), residual renal function (r = -0.359, p < 0.012), and AI (r = -0.304, p = 0.038). In multivariate adjusted analysis, FGF23 was associated with LVMI (β = 0.298, p = 0.041), serum Pi (β = 0.345, p = 0.018), and age (β = -0.372, p = 0.007) independent of dialysis vintage, gender, residual renal function (RRF), albumin, C-reactive protein and systolic blood pressure. There were no associations found between FGF23 and RHI, AI, or VC in multivariable- adjusted models.
Our results show that FGF23 is associated with LVH but not with endothelial dysfunction, arterial stiffness, or vascular calcification in PD patients.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Biomarkers - blood</subject><subject>Blood Pressure - physiology</subject><subject>C-Reactive Protein - analysis</subject><subject>Creatinine - blood</subject><subject>Cross-Sectional Studies</subject><subject>Echocardiography - methods</subject><subject>Endothelium, Vascular - pathology</subject><subject>Female</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Humans</subject><subject>Hyperemia - blood</subject><subject>Hypertrophy, Left Ventricular - blood</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Kidney - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Peritoneal Dialysis - adverse effects</subject><subject>Phosphates - blood</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Serum Albumin - analysis</subject><subject>Urea - blood</subject><subject>Uremia - complications</subject><subject>Vascular Calcification - etiology</subject><subject>Vascular Stiffness - physiology</subject><issn>0301-0430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkLFOwzAURT2AaClIfAHyyEDAjp3EGVFFAQnBAnP04rwQozQOttMqn8BfE9QWpjfco_OkQ8gFZzeJ5PJ2-cKZynh6ROZMMB4xKdiMnHr_yVjMlFAnZBanSgjB2Jx8r0zpbNmCD_TD2W1oaA06WEdjQY2n4L3VBgJWdGumscU60A12wRk9tOBoM_bogrN9M17TzoYdNjhcG0034CfK9hCakZqOTqgJtkNoaWWgHf30YRrN5PNn5LiG1uP5_i7I--r-bfkYPb8-PC3vniMtOAuRzDJQyLVOQaVQqhJirGOlSlalmguOTCZZlUCFudQ5llIqEcdQ6UxLqFIuFuRq5-2d_RrQh2JtvMa2hQ7t4AuepXGe5IKl_6h21nuHddE7swY3FpwVv7GLQ-wJvdxbh3KN1R94KC1-AGggfzA</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Sarmento-Dias, Margarida</creator><creator>Santos-Araújo, Carla</creator><creator>Poínhos, Rui</creator><creator>Oliveira, Bruno</creator><creator>Silva, Isabell Soares</creator><creator>Silva, Liliana Simões</creator><creator>Sousa, Maria João</creator><creator>Correia, Flora</creator><creator>Pestana, Manuel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients</title><author>Sarmento-Dias, Margarida ; Santos-Araújo, Carla ; Poínhos, Rui ; Oliveira, Bruno ; Silva, Isabell Soares ; Silva, Liliana Simões ; Sousa, Maria João ; Correia, Flora ; Pestana, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-477a8e1cc6a86ab8ba2ef288b0d6c131e0457d5ade94c9eb448322adc7c4ad613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Biomarkers - blood</topic><topic>Blood Pressure - physiology</topic><topic>C-Reactive Protein - analysis</topic><topic>Creatinine - blood</topic><topic>Cross-Sectional Studies</topic><topic>Echocardiography - methods</topic><topic>Endothelium, Vascular - pathology</topic><topic>Female</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Humans</topic><topic>Hyperemia - blood</topic><topic>Hypertrophy, Left Ventricular - blood</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Kidney - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Peritoneal Dialysis - adverse effects</topic><topic>Phosphates - blood</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Serum Albumin - analysis</topic><topic>Urea - blood</topic><topic>Uremia - complications</topic><topic>Vascular Calcification - etiology</topic><topic>Vascular Stiffness - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarmento-Dias, Margarida</creatorcontrib><creatorcontrib>Santos-Araújo, Carla</creatorcontrib><creatorcontrib>Poínhos, Rui</creatorcontrib><creatorcontrib>Oliveira, Bruno</creatorcontrib><creatorcontrib>Silva, Isabell Soares</creatorcontrib><creatorcontrib>Silva, Liliana Simões</creatorcontrib><creatorcontrib>Sousa, Maria João</creatorcontrib><creatorcontrib>Correia, Flora</creatorcontrib><creatorcontrib>Pestana, Manuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarmento-Dias, Margarida</au><au>Santos-Araújo, Carla</au><au>Poínhos, Rui</au><au>Oliveira, Bruno</au><au>Silva, Isabell Soares</au><au>Silva, Liliana Simões</au><au>Sousa, Maria João</au><au>Correia, Flora</au><au>Pestana, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients</atitle><jtitle>Clinical nephrology</jtitle><addtitle>Clin Nephrol</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>85</volume><issue>3</issue><spage>135</spage><epage>141</epage><pages>135-141</pages><issn>0301-0430</issn><abstract>Cardiovascular (CV) events are the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), including those patients on peritoneal dialysis (PD). Fibroblast growth factor 23 (FGF23) has been associated with left ventricular hypertrophy (LVH) and mortality in patients with CKD. However, the role of FGF23 in uremic vasculopathy remains unclear. In this study, we aimed to assess the relationship between FGF23 and LVH, endothelial dysfunction, vascular calcification, and arterial stiffness in 48 stable PD patients.
Left ventricular mass index (LVMI) was assessed using 2-D echocardiography. Intact FGF23 blood levels were evaluated using an ELISA kit (Immutopics, Inc., San Clemente, CA, USA). Reactive hyperemia index (RHI) is a surrogate marker of endothelial dysfunction and the augmentation index (AI) is a surrogate marker of arterial stiffness. Both were assessed using peripheral arterial tonometry (EndoPAT 2000). Vascular calcification (VC) was assessed using the Adragão score.
In unadjusted analysis; FGF23 was positively correlated with serum Pi (r = 0.487, p < 0.001), serum urea (r = 0.351, p = 0.015), serum creatinine (r = 0.535, p < 0.001), dialysis vintage (r = 0.309, p = 0.033), and LVMI (r = 0.369, p = 0.027) and was negatively correlated with age (r = -0.343, p = 0.017), residual renal function (r = -0.359, p < 0.012), and AI (r = -0.304, p = 0.038). In multivariate adjusted analysis, FGF23 was associated with LVMI (β = 0.298, p = 0.041), serum Pi (β = 0.345, p = 0.018), and age (β = -0.372, p = 0.007) independent of dialysis vintage, gender, residual renal function (RRF), albumin, C-reactive protein and systolic blood pressure. There were no associations found between FGF23 and RHI, AI, or VC in multivariable- adjusted models.
Our results show that FGF23 is associated with LVH but not with endothelial dysfunction, arterial stiffness, or vascular calcification in PD patients.</abstract><cop>Germany</cop><pmid>26833300</pmid><doi>10.5414/CN108716</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-0430 |
| ispartof | Clinical nephrology, 2016-03, Vol.85 (3), p.135-141 |
| issn | 0301-0430 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1762959306 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Age Factors Biomarkers - blood Blood Pressure - physiology C-Reactive Protein - analysis Creatinine - blood Cross-Sectional Studies Echocardiography - methods Endothelium, Vascular - pathology Female Fibroblast Growth Factors - blood Humans Hyperemia - blood Hypertrophy, Left Ventricular - blood Hypertrophy, Left Ventricular - etiology Kidney - physiopathology Male Middle Aged Peritoneal Dialysis - adverse effects Phosphates - blood Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - complications Serum Albumin - analysis Urea - blood Uremia - complications Vascular Calcification - etiology Vascular Stiffness - physiology |
| title | Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T17%3A25%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20growth%20factor%2023%20is%20associated%20with%20left%20ventricular%20hypertrophy,%20not%20with%20uremic%20vasculopathy%20in%20peritoneal%20dialysis%20patients&rft.jtitle=Clinical%20nephrology&rft.au=Sarmento-Dias,%20Margarida&rft.date=2016-03-01&rft.volume=85&rft.issue=3&rft.spage=135&rft.epage=141&rft.pages=135-141&rft.issn=0301-0430&rft_id=info:doi/10.5414/CN108716&rft_dat=%3Cproquest_cross%3E1762959306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762959306&rft_id=info:pmid/26833300&rfr_iscdi=true |